CA2989161A1 - Ethynylxanthines, leurs preparations et leurs utilisations pour traiter le cancer - Google Patents
Ethynylxanthines, leurs preparations et leurs utilisations pour traiter le cancerInfo
- Publication number
- CA2989161A1 CA2989161A1 CA2989161A CA2989161A CA2989161A1 CA 2989161 A1 CA2989161 A1 CA 2989161A1 CA 2989161 A CA2989161 A CA 2989161A CA 2989161 A CA2989161 A CA 2989161A CA 2989161 A1 CA2989161 A1 CA 2989161A1
- Authority
- CA
- Canada
- Prior art keywords
- 4alkyl
- 3alkyl
- purine
- dione
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/LV2015/000001 WO2016159745A1 (fr) | 2015-03-27 | 2015-03-27 | Ethynylxanthines, leurs préparations et leurs utilisations pour traiter le cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2989161A1 true CA2989161A1 (fr) | 2016-10-06 |
CA2989161C CA2989161C (fr) | 2022-03-01 |
Family
ID=52815227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2989161A Active CA2989161C (fr) | 2015-03-27 | 2015-03-27 | Ethynylxanthines, leurs preparations et leurs utilisations pour traiter le cancer |
Country Status (3)
Country | Link |
---|---|
CA (1) | CA2989161C (fr) |
GB (1) | GB2553684B (fr) |
WO (1) | WO2016159745A1 (fr) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2166948C1 (ru) | 2000-05-29 | 2001-05-20 | Центральный научно-исследовательский рентгенорадиологический институт | Способ лечения глиом с эпилептическим синдромом |
EP1939197A1 (fr) | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | Derivés de 8-éthinylxanthine comme antagonistes selectives du recepteur A2A |
KR101610005B1 (ko) * | 2007-08-17 | 2016-04-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Fab 관련 질환의 치료에 사용하기 위한 푸린 유도체 |
WO2011005871A1 (fr) * | 2009-07-07 | 2011-01-13 | Pgxhealth, Llc | 8-[6-carbonylamino-3-pyridyle] xanthines substituées en tant quantagonistes de ladénosine a2b |
PE20151779A1 (es) | 2013-03-15 | 2015-11-20 | Hydra Biosciences Inc | Xantinas sustituidas y metodos de uso de las mismas |
-
2015
- 2015-03-27 WO PCT/LV2015/000001 patent/WO2016159745A1/fr active Application Filing
- 2015-03-27 CA CA2989161A patent/CA2989161C/fr active Active
- 2015-03-27 GB GB1714548.3A patent/GB2553684B/en active Active
Also Published As
Publication number | Publication date |
---|---|
GB2553684A8 (en) | 2018-04-18 |
GB2553684B (en) | 2020-06-03 |
GB2553684A (en) | 2018-03-14 |
CA2989161C (fr) | 2022-03-01 |
WO2016159745A1 (fr) | 2016-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6919922B2 (ja) | Fgfr4阻害剤、その製造方法と薬学的な応用 | |
EP3719012B1 (fr) | Dérivés de n-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophényl]-3-(4-fluorophényl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide en tant qu'inhibiteurs de c-met/axl pour le traitement des tumeurs | |
JP6951767B2 (ja) | 抗癌薬として使用される複素環式化合物 | |
CA2698018C (fr) | Composes tricycliques ayant une activite cytostatique et/ou cytotoxique et leurs procedes d'utilisation | |
JP5649614B2 (ja) | 有機化合物 | |
KR20060120393A (ko) | 글리코겐 신타아제 키나제 3 저해제로서의트리아졸로피리미딘 유도체 | |
JP7100693B2 (ja) | テトラヒドロプロトベルベリン系化合物、その製造方法、使用及び医薬組成物 | |
WO2022007841A1 (fr) | Inhibiteur de l'egfr, procédé de préparation associé, et application pharmaceutique associée | |
JP2023145547A (ja) | Cd73阻害剤、その製造方法と応用 | |
KR20150119401A (ko) | 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물 | |
CN104557871A (zh) | 具有螺环取代基的芳基吗啉类化合物,其制备方法和用途 | |
CN104557913B (zh) | 吡啶并嘧啶类化合物,其制备方法和用途 | |
El-Gamal et al. | Diarylureas and diarylamides with pyrrolo [2, 3-d] pyrimidine scaffold as broad-spectrum anticancer agents | |
CN111116585B (zh) | 具有c-MET激酶抑制活性化合物、制备方法、组合物及用途 | |
Bu et al. | Synthesis and cytotoxic activity of N-[(alkylamino) alkyl] carboxamide derivatives of 7-oxo-7H-benz [de] anthracene, 7-oxo-7H-naphtho [1, 2, 3-de] quinoline, and 7-oxo-7H-benzo [e] perimidine | |
Guillonneau et al. | Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues | |
Ghoneim et al. | Synthesis of some new hydroquinoline and pyrimido [4, 5-b] quinoline derivatives | |
ES2896938T3 (es) | Inhibidores de GSK-3 | |
CA2989161C (fr) | Ethynylxanthines, leurs preparations et leurs utilisations pour traiter le cancer | |
Costa et al. | Synthesis of novel chromene scaffolds for adenosine receptors | |
EP3036227B1 (fr) | Procédé pour préparer un composé | |
AL-SULTANI et al. | Antioxidant Activity of some New synthesised benzo [d] imidazo [2, 1-b] thiazole derivatives. | |
KR101035709B1 (ko) | 신규2-치환아미노알킬레닐옥시-3-치환페닐에티닐-6-아미노퀴녹살린 유도체 | |
WO2016159747A1 (fr) | Éthynylxanthines, préparation et utilisation de ces composés en tant que modulateurs des canaux calciques | |
WO2016159746A1 (fr) | Nouvelles éthynylxanthines, leur préparation et leur utilisation en tant qu'inhibiteurs de métalloprotéinases matricielles et d'angiogenèse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20200319 |